30-Sep-11 | 30-Sep-10 | 30-Sep-09 | ||||
---|---|---|---|---|---|---|
Revenue | ||||||
Asia | n/a | n/a | 0.13 | 19% | 0.12 | 14% |
Europe | 0.01 | 7% | 0.57 | 81% | 0.61 | 70% |
South Africa | 0.06 | 93% | n/a | n/a | n/a | n/a |
UK | n/a | n/a | n/a | n/a | 0.14 | 16% |
Total | 0.07 | 100% | 0.70 | 100% | 0.87 | 100% |
Profit Before Tax | ||||||
Unanalysed | (8.17) | 100% | (4.21) | 100% | (4.20) | 100% |
Total | (8.17) | 100% | (4.21) | 100% | (4.20) | 100% |
30-Sep-11 | 30-Sep-10 | 30-Sep-09 | ||||
---|---|---|---|---|---|---|
Revenue | ||||||
R&D of Pharmaceutical products | 0.07 | 100% | 0.70 | 100% | n/a | n/a |
Total | 0.07 | 100% | 0.70 | 100% | 0.87 | n/a |
Profit Before Tax | ||||||
R&D of Pharmaceutical products | (8.17) | 100% | (4.21) | 100% | n/a | n/a |
Total | (8.17) | 100% | (4.21) | 100% | (4.20) | n/a |
You are here: research